Biolinq

Company profile

About Biolinq

Biolinq Incorporated is a medical device company that has developed a revolutionary needle-free continuous glucose monitoring platform. The company's flagship product, Biolinq Shine, is an FDA-cleared autonomous intradermal glucose sensor that uses an array of ultra-small electrochemical microsensors combined with an accelerometer and ambient light sensor. Unlike traditional CGM devices, Biolinq Shine requires no hypodermic needle for insertion and features a unique LED light system that provides real-time visual feedback on glucose levels—blue indicates target range, yellow signals high glucose. The device automatically tracks physical activity and sleep patterns to provide contextual insights into how lifestyle factors impact glucose levels. The system is designed for persons 22 years or older not on insulin to aid in the management of conditions related to glycemic control. Biolinq's proprietary microarray platform technology has been developed over 10 years with $120 million in investment and over 500,000 hours of clinical data. The company's multi-sensor platform has potential applications beyond glucose monitoring, with partnerships with leading universities and bioengineering institutions exploring additional biomarker sensing capabilities. The company brings together expertise in biosensor design, consumer electronics, software-derived insights, microarray platform architecture, and proprietary materials science, with a leadership team drawing from extensive experience at companies like Dexcom, Medtronic, and other major medical device manufacturers.

Company description · Biolinq official website